Idt Australia Limited · ASX:IDT
Idt Australia — Investor Presentation (May 2023)
19 slides from Idt Australia's investor presentation, May 23, 2023
Slide 1: Investor Presentation
ASX ANNOUNCEMENT 23 May 2023 Investor Presentation _____________________________________________________________ Please find attached an investor presentation for IDT Australia Limited (ASX: IDT) to be given by Mr Paul McDonald, CEO of IDT Australia Limited and Mr Mark Simari, Chairman of IDT Austra
Slide 2: IDT Australia Investor Presentation May 2023
1 IDT Australia Investor Presentation May 2023
Slide 3: Disclaimer and Important Notices
Disclaimer and Important Notices This presentation has been prepared by IDT Australia Limited ACN 006 522 970 (Company). It contains general implied, as to the accuracy, completeness, likelihood of achievement or reasonableness of any Forward Statement background information only which is current at
Slide 4: Key Investment Highlights
Key Investment Highlights 3 D R U G C O N T R A C T D E V E L O P M E N T & C O N T R A C T M A N U F A C T U R I N G A N E A R L Y A D O P T E R O F T R E N D I N G P H A R M A C U E T I C A L T E C H N O L O G Y World class facilities in Melbourne that are unmatched by MARKET METRICS* other Aust
Slide 5: Meet the Team
MEET THE TEAM 4 N E W L E A D E R S H I P T E A M Mark Simari Chairman Jane Ryan Non-Executive Director Dr Jane Ryan was appointed as a NED in January 2022. She has over 30 years Mark Simari is an experienced and accomplished professional in the of international experience in the pharmaceutical and
Slide 6: Core Business Pillars
CORE BUSINESS PILLARS 5 I D T A U S T R A L I A ’ S B U S I N E S S D I V I S I O N S Established business with two new fast-growth engines • One of the few aseptic sterile fill (injectables) facilities in the world Supplementary services supporting all 3 Advanced Therapies • Focus on and fast-growi
Slide 7: Promising Early Results
PROMISING EARLY RESULTS 6 T U R N A R O U N D S T R A T E G Y G A I N I N G T R A C T I O N IDT AUSTRALIA QUARTERLY SALES $2.5 Sales in the latest quarter jumped 26% to $2.1M vs. 2QFY23 $2.1M Millions and +168% from 1QFY23 $2.0 $1.7M $1.5 Specialty Orals Division driving most of the increase due
Slide 8: Large Addressable Markets
LARGE ADDRESSABLE MARKETS 7 L E V E R A G E D T O M U L T I P L E L U C R A T I V E O P P O R T U N I T I E S Advanced Therapies Specialty Orals API Manufacturing Aseptic Fill & Finish Medicinal Cannabis & (ADC & mRNA) Psychedelics API Production • TAM: Global market forecast to • TAM: Global market
Slide 9: Advanced Therapies
ADVANCED THERAPIES 8 G R O W I N G D E M A N D & L I M I T E D S U P P L Y How we make Advanced Therapies IDT manufactures advanced therapies using Aseptic Sterile Processing (ASP) – a process that ensures every part of the manufacturing chain is free of contaminants. This is critical for some drugs
Slide 10: Advanced Therapies: Long Term High Growth Markets
ADVANCED THERAPIES 9 L O N G T E R M H I G H G R O W T H M A R K E T S Global sterile manufacturing market expected to grow by >50%1 IDT is targeting higher rates of growth than the global market as it US$ billion has the capability to manufacture mRNA and ADC (Antibody Drug Conjugates) technologies
Slide 11: Specialty Orals: Key Driver of Near-Term Growth
SPECIALTY ORALS 10 K E Y D R I V E R O F N E A R - T E R M G R O W T H IDT Australia has the licensure, capabilities and facilities to manufacture a range of medicinal cannabis products for local and international markets. Only automated large-scale Good Manufacturing Practice (GMP) production fac
Slide 12: Specialty Orals: Additional Growth Opportunity in Psychedelics
SPECIALTY ORALS 11 A D D I T I O N A L G R O W T H O P P O R T U N I T Y I N P S Y C H E D E L I C S The Therapeutic Goods Administration (TGA) will permit prescribing of MDMA for the treatment of post-traumatic stress disorder (PTSD) and psilocybin for treatment-resistant depression from 1 July 202
Slide 13: API Manufacturing
API MANUFACTURING 12 L A R G E S T E S T A B L I S H E D L E A D E R Active Pharmaceutical Products Cytotoxic (cancer) & Non-Cytotoxic (anti-infectives) Active Pharmaceutical Ingredient (API) is the Largest independent API manufacturing facility in active component in Australia drugs which produce
Slide 14: Sales Cycle
SALES CYCLE 13 L O N G A N D G R O W I N G R E V E N U E T A I L Pharmaceutical groups appoint IDT ahead of their Phase 1 clinical trials Order size typically increases exponentially as Product Lifecycle trials progress through to Phase 3 and commercialisation Market Contract Value Expansion &
Slide 15: Long Growth Runway
LONG GROWTH RUNWAY 14 S A L E S P I P E L I N E C O N T I N U E S T O G R O W Current Revenue Generating Projects Stage of Projects Phase 1 Phase 2 Phase 3 SAS* Commercial Product Lifecycle 3 1 1 3 Market Contract Value Expansion & Value Add 5 4 3 1 Advanced API Orals Therapies Ph1 Ph 2 Ph 3 SAS/Com
Slide 16: Balance Sheet Strength
BALANCE SHEET STRENGTH 15 L A T E N T V A L U E 31 Dec 2022 $000 Assets Assets Current assets Current assets Cash and cash equivalents 4,325 Trade and other receivables 2,032 Inventories 657 Current tax assets 977 Total current assets 7,991 Net cash of $4.3M Non-current assets Non-current assets P
Slide 17: Outlook
OUTLOOK 16 S I G N I F I C A N T D R I V E R S Two new and significant growth opportunities in Orals and Advance Therapies API sales restimulated through Specialty Orals & Advanced Therapies Plenty of room to grow sales pipeline given current Advanced capacity and capabilities Therapies: Growth mRNA
Slide 18: Glossary
17 Glossary ADC Antibody Drug Conjugate MDMA Methylene-dioxy-meth-amphetamine API Active Pharmaceutical Ingredient ODC Office of Drug Control ASP Aseptic Sterile Processing PTSD Post Traumatic Stress Disorder CDMO Contract Development & Manufacturing Organisation SAS Special Access Scheme FDA U.S. F
Slide 19: IDT Australia
18 IDT Australia